• Journal of Microbiology and Biotechnology
• /
• 제12권4호
• /
• pp.622-627
• /
• 2002

Diphtheria toxin repressor (DtxR) binds to approximately 30 to 35-bp regions containing an interrupted 9-bp inverted repeat within a 19-bp core sequence. The core sequence is fairly conserved and critical for DtxR binding. The flanking regions that are consisted of 5 to 8 more of nucleotides from the core are also required for DtxR binding. The nucleotides in both flanking regions are A-T rich. To examine whether the A-T nucleotides in both flanking regions from the core have significant roles for DtxR binding, a DNA fragment was constructed based on the diphtheria tox promoter/operator, and DNA fragments with substitution of A and T nucleotides In the flanking regions to G and C were also constructed. To assess the effect of these substitutions on binding of DtxR and repressibility by DtxR, $\beta$-galactosidase activity from lacZ fused to the region was assessed. Gel mobility shift of the region by purified DtxR was also examined. The DNA fragments containing the mutations in the flanking regions still exhibited repression and mobility shift with DtxR. The core segment with the mutation is still, therefore, recognized by DtxR. Nonetheless, the results from the assays indicated that the substitution significantly decreased repression of the operator by DtxR in vivo under high-iron condition and decreased binding of DtxR to the operator. These results suggest that A and T nucleotides fur both flanking regions are preferred for the binding of DtxR.

• The Korean Journal of Physiology and Pharmacology
• /
• 제21권1호
• /
• pp.45-54
• /
• 2017

Our study aims to determine the metabolism and excretion of novel pulmonary-targeting docetaxel liposome (DTX-LP) using the in vitro and in vivo animal experimental models. The metabolism and excretion of DTX-LP and intravenous DTX (DTX-IN) in New Zealand rabbits were determined with ultra-performance liquid chromatography tandem mass spectrometry. We found DTX-LP and DTX-IN were similarly degraded in vitro by liver homogenates and microsomes, but not metabolized by lung homogenates. Ultra-performance liquid chromatography tandem mass spectrometry identified two shared DTX metabolites. The unconfirmed metabolite $M_{un}$ differed structurally from all DTX metabolites identified to date. DTX-LP likewise had a similar in vivo metabolism to DTX-IN. Conversely, DTX-LP showed significantly diminished excretion in rabbit feces or urine, approximately halving the cumulative excretion rates compared to DTX-IN. Liposomal delivery of DTX did not alter the in vitro or in vivo drug metabolism. Delayed excretion of pulmonary-targeting DTX-LP may greatly enhance the therapeutic efficacy and reduce the systemic toxicity in the chemotherapy of non-small cell lung cancer. The identification of $M_{un}$ may further suggest an alternative species-specific metabolic pathway.

• 한국정보과학회논문지:정보통신
• /
• 제37권3호
• /
• pp.243-248
• /
• 2010

시스템에서 UE의 QoS를 보장하면서 효율적인 power saving을 위해 본 논문에서는 delay 정보를 이용하여 3GPP(Third Generation Partnership Project) 규격에서 제시한 DRX/DTX(Discontinuous. Reception/Transmission)의 차등적 적용 MAC 프로토콜을 제안한다. 제안한 MAC 프로토콜은 LTE 기지국에서 각 UE의 QoS를 고려하여 적응적으로 DRX/DTX 주기를 제어한다. UE의 패킷 delay가 적은 경우에 DRX/DTX 주기를 늘려 에너지를 절약하고 패킷 delay가 커지면 기지국의 DRX/DTX 주기를 줄여 delay를 줄이고 UE의 QoS를 보장한다. DRX/DTX의 차등적용에 따른 모의실험 결과 제안된 power saving 방식은 DRX/DTX를 상황에 따라 변화시키지 않는 방식에 비해 개선된 power saving 성능을 제공하며 특히 상황에 맞게 DRX/DTX를 설정하여 UE의 요구사항을 충족시킬 수 있다. 본 논문에서는 LTE 기지국과 UE가 통신하는 환경에서 기지국의 에너지를 절약할 수 있는 MAC protocol을 제안하고 시뮬레이션을 통하여 성능이 향상되었음을 확인한다.

• The Korean Journal of Physiology and Pharmacology
• /
• 제25권5호
• /
• pp.479-488
• /
• 2021

This study aimed to develop docetaxel (DTX) loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (DTX-NPs) and to evaluate the different pharmacological sensitivity of NPs to MCF-7 and MDA-MB-231 breast cancer cells. NPs containing DTX or coumarin-6 were prepared by the nanoprecipitation method using PLGA as a polymer and d-α-tocopherol polyethylene glycol 1000 succinate (TPGS) as a surfactant. The physicochemical properties of NPs were characterized. In vitro anticancer effect and cellular uptake were evaluated in breast cancer cells. The particle size and zeta potential of the DTX-NPs were 160.5 ± 3.0 nm and -26.7 ± 0.46 mV, respectively. The encapsulation efficiency and drug loading were 81.3 ± 1.85% and 10.6 ± 0.24%, respectively. The in vitro release of DTX from the DTX-NPs was sustained at pH 7.4 containing 0.5% Tween 80. The viability of MDA-MB-231 and MCF-7 cells with DTX-NPs was 37.5 ± 0.5% and 30.3 ± 1.13%, respectively. The IC₅₀ values of DTX-NPs were 3.92- and 6.75-fold lower than that of DTX for MDA-MB-231 cells and MCF-7 cells, respectively. The cellular uptake of coumarin-6-loaded PLGA-NPs in MCF-7 cells was significantly higher than that in MDA-MB-231 cells. The pharmacological sensitivity in breast cancer cells was higher on MCF-7 cells than on MDA-MB-231 cells. In conclusion, we successfully developed DTX-NPs that showed a great potential for the controlled release of DTX. DTX-NPs are an effective formulation for improving anticancer effect in breast cancer cells.

• Korean Circulation Journal
• /
• 제52권4호
• /
• pp.265-279
• /
• 2022

Digital health is rapidly growing worldwide and its area is expanding from wellness to treatment due to digital therapeutics (DTx). This study compared DTx in the Korean context with other countries to better understand its political and practical implications. DTx is generally the same internationally, often categorized as software as a medical device. It provides evidence-based therapeutic interventions for medical disabilities and diseases. Abroad, DTx support entailed state subsidies and fundraising and national health insurance coverage. In the case of national health insurance coverage, most cases were applied to mental diseases. Moreover, in Japan, DTx related to hypertension will possibly be under discussion for national health insurance coverage in 2022. In overseas countries, coverage was decided only when the clinical effects were equivalent to those provided by existing technology, and in the UK, real usage data for DTx and associated evaluations were reflected by national health coverage determination. Prices were either determined through closed negotiations with health insurance operating agencies and manufacturers or established based on existing technology. Concerning the current situation, DTx dealing with various diseases including hypertension are expected to be developed near in the future, and the demand for use and compensation will likely increase. Therefore, it is urgent to define and prepare for DTx, relevant support systems, and health insurance coverage listings. Several support systems must be considered, including government subsidies, science/technology funds, and health insurance.

• 방송공학회논문지
• /
• 제15권1호
• /
• pp.29-39
• /
• 2010

본 논문에서는 ATSC (Advanced Television Systems Committee) 지상파 디지털 TV 방송 방식에서의 분산 주파수 망(distributed frequency network)을 위해 개발된 분산중계기(Distributed Translator: DTxR)에 대한 실험실 테스트 결과를 기술하고, 그 결과를 분석한다. DTxR 실험실 테스트는 수신부 테스트와 송신부 테스트로 구분된다. DTxR 수신부 테스트는 dynamic range, 랜덤 잡음, 단일 에코, 인접채널 신호의 간섭 테스트 등을 포함하고, DTxR 송신부 테스트는 출력신호의 품질(대역외 방사, 송신 품질, 위상잡음), 출력신호들의 주파수 일치, TxID (Transmitter Identification) 신호가 상용 수신기에 미치는 영향 평가 등을 포함한다. 실험실 테스트 결과에 의하면, DTxR 수신부는 0~17 us 범위 내의 평균 -2.5 dB의 단일 에코 신호를 제거하며, 랜덤 잡음에 대한 TOV (Threshold of Visibility)는 평균 17.5 dB이다. 또한, DTxR 송신부 출력 신호는 미국의 FCC (Federal Communications Commission) 규격을 만족하며, DTxR 출력신호들의 주파수 차이는 0.001 Hz 보다 작다.

• 인터넷정보학회논문지
• /
• 제24권4호
• /
• pp.15-24
• /
• 2023

Digital therapeutics (DTx) are utilized to replace or supplement drug therapy to treat patients. DTx are developed as a mobile application for portability and convenience. The government requires security verification to be performed on digital medical devices that manage sensitive information during the transmission and storage of patient data. Although safety verification is included in the approval process for DTx, the cybersecurity checklist used as a reference does not reflect the characteristics of mobile applications. This poses the risk of potentially overlooking vulnerabilities during security verification. This study aims to address this issue by comparing and analyzing existing items based on the mobile tactics, techniques, and procedures of MITRE ATT&CK, which manages globally known and occurring vulnerabilities through regular updates. We identify 16 items that require improvement and expand the checklist to 29 items to propose improvement measures. The findings of this study may contribute to the safe development and advancement of DTx for managing sensitive patient information.

• 방송공학회논문지
• /
• 제15권1호
• /
• pp.40-51
• /
• 2010

본 논문에서는 ATSC (Advanced Television Systems Committee) 지상파 디지털 TV 방송 방식에서의 분산 주파수 망(distributed frequency network)을 위해 개발된 분산중계기(Distributed Translator: DTxR)에 대한 필드 테스트 결과를 기술하고, 그 결과를 분석한다. 캐나다 오타와에서 수행된 필드 테스트에서는 두 대의 DTxR 신호가 동시에 수신되는 중첩 지역을 중심으로 안테나 및 수신기 종류에 따른 각 측정 지점의 수신 전계 강도, 잡음 마진, 수신 여부, 수신가능 방위각을 측정하였다. 필드 테스트 결과에 의하면, 두 대의 DTxR이 모두 켜졌을 때 수신 전계 강도 및 잡음 마진은 각각의 DTxR이 켜졌을 때 보다 증가하였지만, 수신율 및 수신가능 방위각은 수신기의 종류에 따라 증가하거나 비슷하였다.

• 전자통신동향분석
• /
• 제39권4호
• /
• pp.73-81
• /
• 2024

As the demand for a healthy life increases and the use of information technology expands, interest in digital healthcare has increased. Among the digital healthcare technologies, digital therapeutics (DTx), which are capable of disease prevention, management, and treatment rather than simple healthcare, are expected to play a key role in future healthcare services. As interest in untact remote treatment that can minimize the risk of viral infection has rapidly increased since the spread of COVID-19, the application of DTx has received much attention because it can partially replace face-to-face treatment for mental illnesses, chronic diseases, and other diseases, reducing concerns about infection. In addition, because of the nature of software, DTx have lower toxicity and fewer side effects than existing treatments and do not require manufacturing, transportation, and storage like general medicines. Hence, they can be supplied in large quantities at low cost and have the advantage of lowering medical costs. However, despite these advantages, it has been pointed out that there are difficulties in investment and universal use because of the complexity of pricing and malpractice compensation. In other words, if it is difficult to prove and measure the improvements in disease management and treatment using DTx and it takes a considerable amount of time and money to do so, it will be difficult to attract investment from stakeholders such as medical providers and pharmaceutical companies. In this paper, we examine the domestic and global application status and development trends of DTx and determine the relevant implications.

• 한국식품과학회지
• /
• 제41권4호
• /
• pp.458-463
• /
• 2009

설사성패류독의 신속정밀 분석조건 확립을 위하여 LC-MS/MS를 사용하여 이동상, 분석용 column 및 collision energy 등을 변화시키면서 시험하였다. 50 mM formic acid와 2 mM ammonium formate가 함유된 acetonitrile 수용액을 이동상으로 사용하였을 때 OA와 DTX1이 검출되었다. Collision energy는 독소 성분에 따라 달리하는 것이 다성분 동시분석에 적합하였으며 OA와 DTX1 고유의 fragment ion들은 48 V 정도에서 최적의 intensity로 확인되었다. Column의 종류에 따라서는 $C_8$ column의 경우 OA, DTX1, DTX3, PTX2 및 YTX 모두 검출 가능하였으나 실제 검출 대상이 OA와 DTX1인 경우에는 일반적으로 사용되는 $C_{18}$ column도 적합한 것으로 확인되었다. 본 연구에서 확립한 LC-MS/MS 분석 조건의 검출한계는 OA와 DTX1 모두 1 ng/g, 정량한계는 각각 3 ng/g이었고, 표준독 성분을 첨가한 시료에서 process efficiency는 굴의 경우 91-118%, 진주담치에서는 96-117%이었고, matrix의 영향은 거의 없었다. 마우스 시험에서 양성을 나타낸 시료를 LCMS/MS법으로 분석한 결과, 일부 시료에서만 OA 및 DTX1이 검출되어 두 시험법의 독성은 일치하지 않았으며 LC-MS/MS법은 마우스 시험법보다 하루 이상 분석시간을 단축할 수 있었다.